Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura.
10.5045/kjh.2009.44.2.108
- Author:
Soo Young BAE
1
;
Yeo Kyeoung KIM
;
Joo Young YOON
;
Sung Ji LEE
;
Dae Eun KIM
;
Sung Yoon REW
;
Seung Dok HONG
;
Dae Ho JO
;
Joon Il HWANG
;
Woo Kyun BAE
;
Hyun Jeong SHIM
;
Jae Sook AHN
;
Deok Hwan YANG
;
Sang Hee CHO
;
Je Jung LEE
;
Ik Joo CHUNG
;
Hyeoung Joon KIM
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. yeokim@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Immune thrombocytopenic purpura;
Rituximab;
Toxic epidermal necrolysis
- MeSH:
Antibodies, Monoclonal, Murine-Derived;
Blister;
Epidermal Necrolysis, Toxic;
Fever;
Humans;
Immunoglobulins;
Korea;
Leukemia, Lymphocytic, Chronic, B-Cell;
Lymphoma, Non-Hodgkin;
Purpura, Thrombocytopenic, Idiopathic;
Rituximab
- From:Korean Journal of Hematology
2009;44(2):108-112
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea.
